NCT06165809
Withdrawn
Phase 1
A Phase I Study to Evaluate the Safety and Tolerance of TQB3015 Tablets With Advanced Malignant Cancer.
ConditionsAdvanced Malignant Neoplasm
InterventionsTQB3015 tablets
Overview
- Phase
- Phase 1
- Intervention
- TQB3015 tablets
- Conditions
- Advanced Malignant Neoplasm
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Locations
- 1
- Primary Endpoint
- Dose Limiting Toxicity (DLT)
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
This study is divided into two stages: dose escalation and dose extension, including a single dose and a multiple dose clinical study. This is a single-center, open, non randomized, single arm study to the safety and tolerability of TQB3015 tables in patients with advanced malignant cancer.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;
- •Age: 18 to 75 years old; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •Advanced malignant tumors confirmed by tissue or cellular pathology and the routine standard treatment was ineffective or lack of effective treatment plans, or patients cannot tolerate the standard treatment;
- •Has at least one assessable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria;
- •The main organs function well;
- •Female patient had no plans to become pregnant and voluntarily took effective contraceptive measures during the study period and until at least 6 months after the last dose of study drug.
Exclusion Criteria
- •Concomitant disease and medical history:
- •There were other malignant tumors occured within 3 years before the first dose of study drug.
- •Has multiple factors affecting oral medication;
- •Unalleviated toxicity ≥ grade 1 according to CTCAE v5.0 due to any previous therapy, excluding hair loss;
- •Major surgical treatment, open biopsy and obvious traumatic injury were performed within 28 days before the study, or have not fully recovered from previous surgery, or are expected to require major surgical surgery during the study period;
- •Arteriovenous thrombotic events occurred within 6 months before the first dose, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism;
- •Have a history of psychotropic drug abuse and can not quit or have mental disorders;
- •Subjects with any severe and/or uncontrolled disease including active hepatitis, immunodeficiency;
- •Tumor-related symptoms and treatment:
- •Has known symptomatic central nervous system metastases and/or cancerous meningitis;
Arms & Interventions
TQB3015 tablets
TQB3015 tables is administered as a single dose or multiple dose, 2-40mg once a day; Oral administration on fast condition, 21 days as a cycle.
Intervention: TQB3015 tablets
Outcomes
Primary Outcomes
Dose Limiting Toxicity (DLT)
Time Frame: At the end of Cycle 1 (Day 21).
DLT will be defined as toxicities that meet pre-defined severity criteria according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 toxicity, and assessed as having a suspected relationship to study drug that occurred from the first dose to the end of the first treatment cycle.
Incidence of abnormal clinical laboratory
Time Frame: 30 days after the last administration.
Incidence of participants with clinical laboratory abnormalities
Maximum tolerated dose (MTD)
Time Frame: At the end of Cycle 1 (Day 21).
MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients.
Recommended Phase II Dose (RP2D)
Time Frame: Baseline up to 24 months
DLT describes side effects of a drug or other treatment that are serious enough to evaluate RP2D of TQB3015 tablets in adult patients with Advanced Malignant Cancer.
Secondary Outcomes
- Serious adverse events (SAE)(30 days after the last administration.)
- Area under the concentration-time curve from zero to infinity (AUC0-∞)(Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.)
- Apparent clearance (CL/F)(Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.)
- Apparent volume of distribution (Vd/F)(Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.)
- Adverse events (AE)(30 days after the last administration.)
- Half-life (t1/2)(Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.)
- Area under the concentration-time curve from zero to last observation (AUC [0-t])(Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.)
- Peak concentration (Cmax)(Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.)
- Time to reach maximum (peak) plasma concentration (Tmax)(Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.)
- Objective response rate (ORR)(From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks.)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant CancerAdvanced Malignant NeoplasmNCT06344351Chia Tai Tianqing Pharmaceutical Group Co., Ltd.27
Not yet recruiting
Phase 1
A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant CancerAdvanced Malignant CancerNCT06415903Chia Tai Tianqing Pharmaceutical Group Co., Ltd.59
Completed
Phase 1
A Clinical Study of TQH2929 in Healthy Adult SubjectsPsoriasisNCT06156280Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.40
Completed
Phase 1
A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT06711991Chia Tai Tianqing Pharmaceutical Group Co., Ltd.48
Terminated
Phase 1
A Phase I Study of RGT-264 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT05764915Regor Pharmaceuticals Inc.11